Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Cytostatic Therapy | Research

Changes in carnitine levels through induction chemotherapy in head and neck cancer patients as a potential cause of therapy-related malaise

Authors: Tatsuya Ito, Kiyoaki Tsukahara, Hiroki Sato, Akira Shimizu, Isaku Okamoto

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Carnitine is related to malaise, and cisplatin is associated with decreased carnitine. The purpose of this study was to elucidate the effects of one course of induction chemotherapy (IC) for head and neck cancer on blood carnitine levels, focusing on free carnitine (FC).

Methods

This single-center prospective study investigated 20 patients diagnosed with primary head and neck cancer who underwent IC with cisplatin, docetaxel, and 5-fluorouracil. FC, acylcarnitine (AC), and total carnitine (TC) levels were measured before starting therapy and on Days 7 and 21 after starting IC. In addition, malaise was evaluated before and after therapy using a visual analog scale (VAS).

Results

All subjects were men and the most common primary cancer site was the hypopharynx (9 patients). FC levels before starting therapy and on Days 7 and 21 were 47.7 ± 2.2 μM/mL, 56.7 ± 2.2 μM/mL, and 41.1 ± 1.9 μM/mL, respectively. Compared with the baseline before starting therapy, FC had significantly decreased on Day 21 (p = 0.007). AC levels before starting therapy and on Days 7 and 21 were 12.5 ± 1.2 μM/mL, 13.6 ± 1.4 μM/mL, and 10.7 ± 0.7 μM/mL, respectively. TC levels before starting therapy and on Days 7 and 21 were 60.2 ± 2.5 μM/mL, 70.2 ± 3.3 μM/mL, and 51.7 ± 2.3 μM/mL, respectively. No significant differences in AC, TC or VAS were seen before the start of therapy and on Day 21.

Conclusions

After IC, a latent decrease in FC occurred without any absolute deficiency or subjective malaise.

Ida S, et al. Guidelines for diagnosis and treatment of carnitine deficiency 2018. Japan Pediatr Soc. 2019;123:1–6. http://www.jpeds.or.jp/uploads/files/20181207_shishin.pdf. Accessed 16 June 2021.

Vinci E, Rampello E, Zanoli L, Oreste G, Pistone G, Malaguarnera M. Serum carnitine levels in patients with tumoral cachexia. Eur J Intern Med. 2005;16(6):419–23. https://doi.org/10.1016/j.ejim.2005.02.014.CrossRefPubMed

Malaguarnera M, Risino C, Gargante MP, Oreste G, Barone G, Tomasello AV, et al. Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroenterol. 2006;12(28):4541–5. https://doi.org/10.3748/wjg.v12.i28.4541.CrossRefPubMedPubMedCentral

Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet. 2012;51(9):553–72. https://doi.org/10.1007/BF03261931.CrossRefPubMed

Cruciani RA, Dvorkin E, Homel P, Malamud S, Culliney B, Lapin J, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manag. 2006;32(6):551–9. https://doi.org/10.1016/j.jpainsymman.2006.09.001.CrossRef

Clelia M, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr. 2012;31:176–82.CrossRef

Gramignano G, et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 2015;22:136–45.CrossRef

Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, et al. L-carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clin Nutr. 2012;31(6):889–95. https://doi.org/10.1016/j.clnu.2012.03.005.CrossRefPubMed

Wanner C, Wäckerle B, Boeckle H, Schollmeyer P, Hörl WH. Plasma and red blood cell carnitine and carnitine esters during L-carnitine therapy in hemodialysis patients. Am J Clin Nutr. 1990;51(3):407–10. https://doi.org/10.1093/ajcn/51.3.407.CrossRefPubMed

10.

Ferrari R, et al. L-Carnitine and its role in medicine: from function to therapy. London: Academic Press; 1992. p. 381–400.

11.

Guder WG, et al. The role of the kidney in carnitine metabolism. J Clin Chem Clin Biochem. 1990;28:347–50.PubMed

12.

Lancaster CS, Hu C, Franke RM, Filipski KK, Orwick SJ, Chen Z, et al. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res. 2010;16(19):4789–99. https://doi.org/10.1158/1078-0432.CCR-10-1239.CrossRefPubMedPubMedCentral

13.

Laird BJA, et al. Pain, Depression, and Fatigue as a symptom cluster in Advanced Cancer. J Pain Symptom Manag. 2011;42(1):1-11. https://doi.org/10.1016/j.jpainsymman.2010.10.261.

14.

Jager-Wittenaar H, Dijkstra PU, Vissink A, van der Laan BFAM, van Oort RP, Roodenburg JLN. Critical weight loss in head and neck cancer—prevalence and risk factors at diagnosis: an explorative study. Support Care Cancer. 2007;15(9):1045–50. https://doi.org/10.1007/s00520-006-0212-9.CrossRefPubMed

15.

Chencharick JD, Mossman KL. Nutritional consequences of the radiotherapy of head and neck cancer. Cancer. 1983;51(5):811–5. https://doi.org/10.1002/1097-0142(19830301)51:5<811::AID-CNCR2820510511>3.0.CO;2-M.CrossRefPubMed

16.

Gillison ML. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck. 2007;29(8):779–92. https://doi.org/10.1002/hed.20573.CrossRefPubMed

17.

Tsukahara K, Nakamura K, Motohashi R, Sato H, Endo M, Katsube Y, et al. Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas. Acta Otolaryngol. 2014;134(11):1198–204. https://doi.org/10.3109/00016489.2014.913314.CrossRefPubMed

18.

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33. https://doi.org/10.1126/science.1160809.CrossRefPubMedPubMedCentral

19.

Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, et al. Na (+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999;291(2):778–84.PubMed

20.

Hu C, Lancaster CS, Zuo Z, Hu S, Chen Z, Rubnitz JE, et al. Inhibition of OCTN2-mediated transport of carnitine by etoposide. Mol Cancer Therap. 2012;11(4):921–9. https://doi.org/10.1158/1535-7163.MCT-11-0980.CrossRef

21.

Hockenberry MJ, Hooke MC, Gregurich MA, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol. 2009;31(9):664–9. https://doi.org/10.1097/MPH.0b013e3181b259a7.CrossRefPubMed

22.

Okubo H, Ando H, Ishizuka K, Kitagawa R, Okubo S, Saito H, et al. Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma. PLoS One. 2020;15(3):e0229772. https://doi.org/10.1371/journal.pone.0229772.CrossRefPubMedPubMedCentral

23.

Baussard L, Stoebner-Delbarre A, Bonnabel L, Huteau ME, Gastou A, Cousson-Gélie F. Development and validation of the daily fatigue cancer scale (DFCS): single-item questions for clinical practice. Eur J Oncol Nurs. 2017;26:42–8. https://doi.org/10.1016/j.ejon.2016.12.004.CrossRefPubMed

24.

Schmidt-Sommerfeld E, Werner D, Penn D. Carnitine plasma concentrations in 353 metabolically healthy children. Eur J Pediatr. 1988;147(4):356–60. https://doi.org/10.1007/BF00496410.CrossRefPubMed

25.

Hauser K, Walsh D. Visual analogue scales and assessment of quality of life in cancer. J Support Oncol. 2008;6(6):277–82.PubMed

Title: Changes in carnitine levels through induction chemotherapy in head and neck cancer patients as a potential cause of therapy-related malaise
Authors: Tatsuya Ito
Kiyoaki Tsukahara
Hiroki Sato
Akira Shimizu
Isaku Okamoto
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08471-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients

Infiltration of CD1a-positive dendritic cells in advanced laryngeal cancer correlates with unfavorable outcomes post-laryngectomy

The Will Rogers phenomenon, breast cancer and race

Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis

Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer